Document Detail

Pay for performance and beyond.
MedLine Citation:
PMID:  20528417     Owner:  NLM     Status:  In-Data-Review    
Pay for performance has become almost a cliché in health policy discussions during the past 5 years. Proponents and opponents have tended to take sides based largely on abstractions, but in reality pay for performance is likely to be more beneficial than critics allow and less transformational than its strongest advocates suggest. Both economic theory and common sense support the notion that payment for healthcare should be determined, at least in part, based on meaningful indicators of quality or value, but precisely how this should occur depends on a number of factors, including the importance of patient differences and the nature of physician motivation. Despite considerable investment in both the infrastructure for and operating expenses of pay for performance, we have learned very little to date that is useful for determining how much and in what way performance should influence provider payment in healthcare. Looking ahead, it seems likely that performance incentives will remain part of the reimbursement landscape, but that payers and policy makers will turn their attention to more comprehensive payment reform. Novel mixed payment (i.e., part prospective, part fee for service and part pay for performance) models have emerged as the most promising proposals for such reform.
Meredith B Rosenthal
Related Documents :
17577967 - Section 506 of the medicare prescription drug, improvement, and modernization act of 20...
10161557 - Federal employees health benefits program: limitation on physician charges and fehb pro...
15762897 - Medicare expenditures for residents in assisted living: data from a national study.
10300857 - Reimbursement rates for health care services authorized under the indian health service...
15364147 - Pricing health services for purchasers--a review of methods and experiences.
11218627 - Patient's needs in substitutive dialysis treatment. some psycho-social and organization...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of pharmacoeconomics & outcomes research     Volume:  7     ISSN:  1744-8379     ISO Abbreviation:  Expert Rev Pharmacoecon Outcomes Res     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2010-06-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132257     Medline TA:  Expert Rev Pharmacoecon Outcomes Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  351-5     Citation Subset:  -    
Department of Health Policy & Management, Harvard School of Public Health, 677 Huntington Avenue, Boston MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spinal cord stimulation for refractory chronic angina pectoris: influence on quality of life.
Next Document:  Cost-effectiveness of antiplatelet therapy for secondary stroke prevention.